MiMedx sees FY25 revenue up low double-digits percent

Sees FY25 adjusted EBITDA margin above 20%. The company said, “Longer-term, the Company continues to expect to achieve annual net sales growth in the low double-digits as a percentage with an adjusted EBITDA margin above 20%.”